(PPH) Pharmaceutical - Overview
Etf: Pharmaceutical, Biotech, Prescription, Generic, Vaccine
Dividends
| Dividend Yield | 2.00% |
| Yield on Cost 5y | 2.91% |
| Yield CAGR 5y | 10.09% |
| Payout Consistency | 88.8% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 15.5% |
| Relative Tail Risk | -0.33% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.01 |
| Alpha | 13.93 |
| Character TTM | |
|---|---|
| Beta | 0.427 |
| Beta Downside | 0.414 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.06% |
| CAGR/Max DD | 0.79 |
Description: PPH Pharmaceutical December 26, 2025
The VanEck Pharmaceutical ETF (NASDAQ: PPH) is a U.S.-based, health-sector ETF that tracks a benchmark index of U.S. exchange-listed pharmaceutical companies, including mid-cap firms and foreign ADRs. By mandate, the fund invests at least 80 % of its assets in the index constituents, making it a non-diversified vehicle focused on the pharma space.
Key metrics as of the latest filing: the fund holds roughly $400 million in assets under management, carries an expense ratio of 0.45 %, and its top five holdings-such as Pfizer, Merck, and Amgen-represent about 30 % of the portfolio. The pharmaceutical sector is currently driven by strong R&D pipelines, an aging global population, and a robust pipeline of FDA-approved drugs, which together support revenue growth expectations of 6-8 % annually for the industry.
Investors should monitor macro-level drivers like healthcare spending growth (projected to rise ~5 % YoY) and policy shifts around drug pricing, as these can materially affect the fund’s performance.
For a deeper dive into PPH’s risk profile and comparative analysis, you may find ValueRay’s analytical tools useful.
What is the price of PPH shares?
Over the past week, the price has changed by +1.05%, over one month by +4.25%, over three months by +16.82% and over the past year by +24.11%.
Is PPH a buy, sell or hold?
What are the forecasts/targets for the PPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 124.8 | 15.4% |
PPH Fundamental Data Overview January 29, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.18b USD (1.18b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.18b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.18b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.49% (E(1.18b)/V(1.18b) * Re(7.49%) + (debt-free company))
Discount Rate = 7.49% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)